{"id":28436,"date":"2022-03-16T12:52:45","date_gmt":"2022-03-16T11:52:45","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=28436"},"modified":"2022-03-17T11:09:53","modified_gmt":"2022-03-17T10:09:53","slug":"vollpublikationen-der-beiden-phase-ii-iii-studien-mit-molnupiravir-bzw-nirmatrelvir-zur-behandlung-nicht-hospitalisierter-patienten-mit-covid-19-und-risikofaktoren-fuer-einen-schweren-verlauf","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/vollpublikationen-der-beiden-phase-ii-iii-studien-mit-molnupiravir-bzw-nirmatrelvir-zur-behandlung-nicht-hospitalisierter-patienten-mit-covid-19-und-risikofaktoren-fuer-einen-schweren-verlauf","title":{"rendered":"Vollpublikationen der beiden Phase-II\/III-Studien mit Molnupiravir bzw. Nirmatrelvir zur Behandlung nicht hospitalisierter Patienten mit COVID-19 und Risikofaktor(en) f\u00fcr einen schweren Verlauf"},"content":{"rendered":"<p>Wir haben bereits im November 2021 und Februar 2022 \u00fcber die beiden antiviral wirksamen Medikamente, Molnupiravir (Lagevrio\u00ae, Merck Sharp &amp; Dohme = MSD) und Nirmatrelvir plus Ritonavir (Paxlovid\u00ae, Pfizer) berichtet (,\u00a0). Da am 10.\u00a0Februar 2022 zu Molnupiravir bzw. am 16.\u00a0Februar 2022 zu Nirmatrelvir plus Ritonavir die Vollpublikationen der f\u00fcr die Zulassung relevanten klinischen Studien im [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben bereits im November 2021 und Februar 2022 \u00fcber die beiden antiviral wirksamen Medikamente, Molnupiravir (Lagevrio\u00ae, Merck Sharp &amp; Dohme = MSD) und Nirmatrelvir plus Ritonavir (Paxlovid\u00ae, Pfizer) berichtet (,\u00a0). Da am 10.\u00a0Februar 2022 zu Molnupiravir bzw. am 16.\u00a0Februar 2022 zu Nirmatrelvir plus Ritonavir die Vollpublikationen der f\u00fcr die Zulassung relevanten klinischen Studien im [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5340,5339,5641,5643,5585,5642,5602,5603,5604,120,5338],"class_list":["post-28436","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-coronavirus","tag-covid-19","tag-epic-hr-studie","tag-lagevrio","tag-molnupiravir","tag-move-out-studie","tag-nirmatrelvir","tag-nirmatrelvir-ritonavir","tag-paxlovid","tag-ritonavir","tag-sars-cov-2"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/28436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=28436"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/28436\/revisions"}],"predecessor-version":[{"id":28437,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/28436\/revisions\/28437"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=28436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=28436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=28436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}